<DOC>
	<DOCNO>NCT02219009</DOCNO>
	<brief_summary>The purpose study determine usability Medical Information Device # 1 ( MIND1 ) system adult schizophrenia treat oral aripiprazole .</brief_summary>
	<brief_title>Open-label Study Assess Usability Medical Information Device # 1 ( MIND1 ) System Adults With Schizophrenia On Oral Aripiprazole</brief_title>
	<detailed_description>Poor adherence medication well-recognized problem psychiatric patient . Although variety treatment model develop improve management patient general medication adherence particular , poor medication adherence remain major barrier achieve optimal health . The MIND1 System include drug-device combination , patch , application software convey level activity rest mark event act ingestion . The purpose open-label study determine usability Medical Information Device # 1 ( MIND1 ) System adults schizophrenia . Approximately 32 subject schizophrenia , 18 65 year age ( inclusive ) currently prescribe stabilize oral aripiprazole , enrol .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects must prepare able give write ( sign date ) inform consent , include adherence study requirement restriction enrol study . Subjects must willing adhere study procedure , include troubleshoot MIND1 System third party need ( third party blind personal health information ) . Male female subject 18 65 year age , inclusive , time informed consent . Subjects primary current diagnosis schizophrenia , define Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criterion . Subjects may symptomatic screening , must able treated outpatient . Subject cooperative , able ingest oral medication , willing complete aspect study . Subject currently prescribe oral aripiprazole schizophrenia one follow single daily dos ( 10 , 15 , 20 , 30 mg ) , deem likely remain stable dose throughout course study . Subject change aripiprazole regimen dose 2 week screen . Subject must able willing carry MIND1 System smartphone his/her person complete task , well adequately operate device , applicable . Caregiver thirdparty assistance utilize , need , although subject encourage attempt task . Subject likely posse capacity utilize technology interface ( eg , open navigate software application use touch screen ) telephone feature smartphone . The subject satisfactory mobile phone reception ( preferably 3 bar , WiFi ) home and/or work studydesignated wireless carrier . Subject pregnant breastfeeding , plan become pregnant . Skin anterior chest low edge rib cage free dermatological problem ( eg , dermatosis dermatitis , open wound , skin disorder wart , rash , atopic dermatitis , irritation ) . Subjects current DSM5 diagnosis schizophrenia , include major depressive disorder , bipolar disorder , schizoaffective disorder , delirium , major neurocognitive disorder ( eg , dementia ) , intellectual developmental disorder , diagnosis might impact subject 's ability participate study . Other disorder focus treatment impact subject 's ability participate aspect study ( eg , social anxiety disorder ) may include . Subjects current DSM5 diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder . Subjects exhibit prominent negative symptom , judgment investigator , interfere study procedure unable adhere study requirement . Subjects currently longacting injectable antipsychotic . Subjects likely incapable use MIND1 System technology , even assistance . On ColumbiaSuicide Severity Rating Scale ( CSSRS ) Subjects answer `` Yes '' Suicidal Ideation Item 4 ( Active Suicidal Ideation Some Intent Act , Without Specific Plan ) whose recent episode meeting criterion CSSRS Item 4 occur within last 3 month , OR Subjects answer `` Yes '' CSSRS Suicidal Ideation Item 5 ( Active Suicidal Ideation Specific Plan Intent ) whose recent episode meeting criterion CSSRS Item 5 occur within last 3 month , OR Subjects answer `` Yes '' 5 CSSRS Suicidal Behavior Items ( actual attempt , interrupt attempt , abort attempt , preparatory act , behavior ) whose recent episode meeting criterion 5 CSSRS Suicidal Behavior Items occur within last 1 year , OR Subjects , opinion investigator , present serious risk suicide . Subject receive investigational product within last 30 day , include MIND1 System ( eg , subject participate Cohort 1 study eligible Cohort 2 ) . Subjects history evidence medical condition would expose undue risk significant AE interfere assessment safety usability course study , include limited , hepatic , renal , respiratory , cardiovascular , endocrine , neurologic , hematologic , immunologic disease , determine clinical judgment investigator . Subjects epilepsy history seizure ( except single childhood febrile seizure , post traumatic seizure , alcohol withdrawal seizure , etc ) . Subjects history neuroleptic malignant syndrome clinically significant tardive dyskinesia , assess investigator . Subjects know allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones . Subjects history hypersensitivity antipsychotic agent . Subjects know allergy adhesive tape pertinent component patch IEM Sexually active woman childbearing potential commit utilize 2 approved birth control method remain abstinent study 30 day follow last dose study medication . Sexually active male ( unless sterile , define bilateral orchiectomy ) commit utilize 2 approved birth control method remain abstinent study 90 day follow last dose study drug . Subject current history ( within past month ) substance use disorder ( exclude tobacco ) meet DSM5 criterion , demonstrate positive result urine drug test screening . Subjects positive drug screen drug abuse ( exclude cannabinoids ) exclude may retested rescreened . Subjects positive urine drug screen result use prescription ( opioids ) overthecounter medication product , investigator 's documented opinion , signal clinical condition would impact safety subject interpretation study result may continue evaluation study follow consultation approval Medical Monitor . Subjects , opinion investigator , acutely psychotic exhibit symptom currently require hospitalization . Subjects unwilling refrain use topical product skin patch site . Subjects unwilling unable complete evaluation include study , include audio record subject 's voice require ability distinguish color ( eg , subject unwilling record colorblind subject exclude participation study ) Any subject , opinion investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>OPC-14597 Digital</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Medical Information Device # 1 System ( MIND1 )</keyword>
	<keyword>Treatment Adherence</keyword>
	<keyword>Ingestible Event Marker</keyword>
</DOC>